{"id":"dwn12088","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4802138","moleculeType":"Small molecule","molecularWeight":"328.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the S1P1 receptor, DWN12088 modulates sphingosine-1-phosphate signaling, which plays a crucial role in various cellular processes, including immune cell trafficking and lymphocyte egress from lymphoid organs.","oneSentence":"DWN12088 is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:36:03.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT05389215","phase":"PHASE2","title":"Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF","status":"RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-07-29","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":102},{"nctId":"NCT04888715","phase":"PHASE1","title":"To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-07-23","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":48},{"nctId":"NCT04767815","phase":"PHASE1","title":"To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-03-22","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":36},{"nctId":"NCT04888728","phase":"PHASE1","title":"To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-06-30","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DWN12088 Xmg Tablet (BID)"],"phase":"phase_2","status":"active","brandName":"DWN12088","genericName":"DWN12088","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWN12088 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}